Omentin-1 prevents inflammation-induced osteoporosis by downregulating the pro-inflammatory cytokines

Shan-Shan Rao,Yin Hu,Ping-Li Xie,Jia Cao,Zhen-Xing Wang,Jiang-Hua Liu,Hao Yin,Jie Huang,Yi-Juan Tan,Juan Luo,Ming-Jie Luo,Si-Yuan Tang,Tuan-Hui Chen,Ling-Qing Yuan,Er-Yuan Liao,Ran Xu,Zheng-Zhao Liu,Chun-Yuan Chen,Hui Xie
DOI: https://doi.org/10.1038/s41413-018-0012-0
IF: 12.7
2018-01-01
Bone Research
Abstract:Osteoporosis is a frequent complication of chronic inflammatory diseases and increases in the pro-inflammatory cytokines make an important contribution to bone loss by promoting bone resorption and impairing bone formation. Omentin-1 is a newly identified adipocytokine that has anti-inflammatory effects, but little is known about the role of omentin-1 in inflammatory osteoporosis. Here we generated global omentin-1 knockout ( omentin-1 −/− ) mice and demonstrated that depletion of omentin-1 induces inflammatory bone loss-like phenotypes in mice, as defined by abnormally elevated pro-inflammatory cytokines, increased osteoclast formation and bone tissue destruction, as well as impaired osteogenic activities. Using an inflammatory cell model induced by tumor necrosis factor-α (TNF-α), we determined that recombinant omentin-1 reduces the production of pro-inflammatory factors in the TNF-α-activated macrophages, and suppresses their anti-osteoblastic and pro-osteoclastic abilities. In the magnesium silicate-induced inflammatory osteoporosis mouse model, the systemic administration of adenoviral-delivered omentin-1 significantly protects from osteoporotic bone loss and inflammation. Our study suggests that omentin-1 can be used as a promising therapeutic agent for the prevention or treatment of inflammatory bone diseases by downregulating the pro-inflammatory cytokines.
What problem does this paper attempt to address?